Gold Intraday: Up Trend Threatened by Vaccine Progress
George Lam July 2, 2020 3:57 AM
On Wednesday, spot gold dropped as much as $30 from the day-high after Pfizer's vaccine results announcement and ended down 0.6% on day.
On Wednesday, U.S. pharmaceutical giant Pfizer and German biotech company BioNTech announced early positive data of its Covid-19 vaccine. Spot gold dropped as much as $30 from the day-high after the announcement and ended down 0.6%.
Pfizer said if the ongoing studies are successful and the vaccine receives regulatory approval, they "expect to manufacture up to 100 million doses by the end of 2020 and potentially more than 1.2 billion doses by the end of 2021".
Unlike the previous vaccine study results released by Moderna in May, scientists praised Pfizer for publishing the data and said the results support progressing to a larger clinical trial.
From an intraday technical point of view, spot gold risks breaking below a longer-term rising trend line as shown on the 1-hour chart. Another RSI bearish divergence is spotted when it marked a new high near $1,789. Unless the nearest resistance at $1,778 is surpassed, which is the 61.8% Fibonacci retracement resistance level of yesterday's decline, spot gold is likely to challenge the 1st and 2nd support at $1,759 and $1,747 respectively. Alternatively, a break above $1,778 might suggest that the next resistance at $1,789 would be tested again.
Source: TradingView, Gain Capital
StoneX Financial Ltd (trading as “City Index”) is an execution-only service provider. This material, whether or not it states any opinions, is for general information purposes only and it does not take into account your personal circumstances or objectives. This material has been prepared using the thoughts and opinions of the author and these may change. However, City Index does not plan to provide further updates to any material once published and it is not under any obligation to keep this material up to date. This material is short term in nature and may only relate to facts and circumstances existing at a specific time or day. Nothing in this material is (or should be considered to be) financial, investment, legal, tax or other advice and no reliance should be placed on it.
No opinion given in this material constitutes a recommendation by City Index or the author that any particular investment, security, transaction or investment strategy is suitable for any specific person. The material has not been prepared in accordance with legal requirements designed to promote the independence of investment research. Although City Index is not specifically prevented from dealing before providing this material, City Index does not seek to take advantage of the material prior to its dissemination. This material is not intended for distribution to, or use by, any person in any country or jurisdiction where such distribution or use would be contrary to local law or regulation.